Harrow, Inc. is an ophthalmic pharmaceutical company founded in December 2011 and headquartered in Nashville, Tennessee. The company specializes in developing, acquiring and commercializing medications used to treat eye diseases and support surgical procedures, with a focus on making effective treatments accessible to eye-care professionals and their patients. Harrow trades on the Nasdaq under the ticker HROW. Over time, the company has evolved from a specialized pharmaceutical compounding business into a broader ophthalmology-focused pharmaceutical company with a portfolio of branded, FDA-approved medicines and proprietary formulations.
Harrow's product portfolio addresses conditions affecting different parts of the eye, including dry eye disease, glaucoma, cataracts, retinal disorders, inflammation and eye infections. Among its established products are VEVYE, a prescription treatment for the signs and symptoms of dry eye disease; IHEEZO, an ophthalmic gel anesthetic used during certain eye procedures; and TRIESENCE, an injectable corticosteroid used to treat certain ophthalmic conditions and help surgeons visualize structures inside the eye during vitrectomy. The company also markets medicines used in surgical settings and treatments intended for chronic eye conditions, giving it relationships with ophthalmologists, optometrists, retinal specialists and eye surgeons.
Harrow's growth strategy has involved acquiring established ophthalmic medicines and expanding their commercial reach. Rather than relying entirely on developing new drugs from the earliest stages of research, the company can acquire commercial rights to existing treatments, improve supply availability and build relationships with physicians who prescribe them. Harrow also owns ImprimisRx, a pharmaceutical compounding business focused on customized medications for ophthalmic and other specialized medical needs. Its broader portfolio includes biosimilar medicines and additional treatments for conditions such as allergic eye disease, providing opportunities to expand into new patient populations and clinical settings.
Harrow combines branded pharmaceutical sales with compounding, licensing arrangements and ongoing product development. Its commercial strategy emphasizes working directly with eye-care professionals to understand clinical needs, improve access to medications and support the adoption of treatments across different practice settings. The company also pursues opportunities to expand the uses and availability of its existing medicines while introducing products acquired from other pharmaceutical developers. By maintaining a portfolio that spans routine eye care, chronic disease management, retinal treatments and ophthalmic surgery, Harrow has built a business focused on several interconnected areas of vision care rather than depending on a single drug or therapeutic category.